Literature DB >> 16056257

Immune responses to tuberculosis in developing countries: implications for new vaccines.

Graham A W Rook1, Keertan Dheda, Alimuddin Zumla.   

Abstract

Tuberculosis is out of control in developing countries, where it is killing millions of people every year. In these areas, the present vaccine - Mycobacterium bovis bacillus Calmette-Guérin (BCG) - is failing. Progressive tuberculosis occurs because the potentially protective T helper 1 (T(H)1)-cell response is converted to an immunopathological response that fails to eliminate the bacteria. Here, we discuss the data indicating that the problem in developing countries is not a lack of adequate T(H)1-cell responses but, instead, an exaggerated tendency to switch to immunopathological responses. We propose that a successful vaccine needs to block this immunopathology, because it is not the quantity of T(H)1-cell activity that matters but, rather, its context.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16056257     DOI: 10.1038/nri1666

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  44 in total

1.  A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.

Authors:  Mushtaq Ahmed; Douglas M Smith; Tarek Hamouda; Javier Rangel-Moreno; Ali Fattom; Shabaana A Khader
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection.

Authors:  Stephan Schwander; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2010-11-12       Impact factor: 21.405

4.  Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.

Authors:  Michael Santosuosso; Sarah McCormick; Xizhong Zhang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 5.  Unfolding the relationship between secreted molecular chaperones and macrophage activation states.

Authors:  Brian Henderson; Samantha Henderson
Journal:  Cell Stress Chaperones       Date:  2008-10-29       Impact factor: 3.667

6.  Endocytosis of Mycobacterium tuberculosis heat shock protein 60 is required to induce interleukin-10 production in macrophages.

Authors:  Nazia Parveen; Raja Varman; Shiny Nair; Gobardhan Das; Sudip Ghosh; Sangita Mukhopadhyay
Journal:  J Biol Chem       Date:  2013-07-11       Impact factor: 5.157

Review 7.  Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD.

Authors:  R N van Zyl Smit; M Pai; W W Yew; C C Leung; A Zumla; E D Bateman; K Dheda
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

8.  Lower levels of interleukin-12 precede the development of tuberculosis among HIV-infected women.

Authors:  José Bordón; Michael W Plankey; Mary Young; Ruth M Greenblatt; Maria C Villacres; Audrey L French; Jie Zhang; Guy Brock; Savitri Appana; Betsy Herold; Helen Durkin; Jonathan E Golub; Rafael Fernandez-Botran
Journal:  Cytokine       Date:  2011-08-30       Impact factor: 3.861

9.  An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice.

Authors:  Vandana Kaul; Debapriya Bhattacharya; Yogesh Singh; Luc Van Kaer; Marc Peters-Golden; William R Bishai; Gobardhan Das
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

10.  Increased pleural soluble fas ligand (sFasL) levels in tuberculosis pleurisy and its relation with T-helper type 1 cytokines.

Authors:  Ferah Budak; Esra Kunt Uzaslan; Sengül Cangür; Güher Göral; Haluk Barbaros Oral
Journal:  Lung       Date:  2008-07-29       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.